
Cardiologytocilizumabcardiovascular risk
Tocilizumab Reduces Major Cardiovascular Events Risk in Giant Cell Arteritis: Insights from a Nationwide French Cohort
By MedXY|Sep 8, 2026
A nationwide observational study reveals tocilizumab use in giant cell arteritis significantly lowers major adverse cardiovascular events compared to methotrexate, highlighting its potential cardiovascular benefits beyond inflammation contr
